{
  "ticker": "JNJ",
  "target_date": "2025-09-10",
  "actual_date": "2025-09-10",
  "collected_at": "2025-12-08T12:15:48.338926",
  "price": {
    "open": 175.19,
    "high": 175.5,
    "low": 173.23,
    "close": 174.680908203125,
    "volume": 6891600,
    "change_1d_pct": -0.66,
    "change_7d_pct": -0.78,
    "change_30d_pct": 5.34
  },
  "technicals": {
    "rsi_14": 41.25,
    "sma_20": 175.57,
    "sma_50": 167.48,
    "macd": 2.391,
    "macd_signal": 3.023,
    "macd_histogram": -0.631,
    "bb_upper": 178.7,
    "bb_lower": 172.45,
    "price_vs_sma20_pct": -0.51,
    "price_vs_sma50_pct": 4.3,
    "volume_ratio": 0.87
  },
  "fundamentals": {
    "market_cap": 487532888064,
    "pe_ratio": 19.532335,
    "forward_pe": 19.090094,
    "price_to_book": 6.141834,
    "price_to_sales": 5.290702,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.62,
    "pct_from_52w_low": 43.84
  },
  "macro": {
    "spy": {
      "price": 650.41,
      "change_1d_pct": 0.29,
      "change_7d_pct": 1.86
    },
    "vix": {
      "level": 15.35,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.03
    },
    "dollar_index": {
      "level": 97.78
    },
    "gold": {
      "price": 3643.6
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Trump\u2019s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.",
      "source": "Yahoo",
      "datetime": 1757533740,
      "summary": "A new Trump administration crackdown on prescription drug ads directed at consumers could substantially drag on pharmaceutical revenues\u2014if it\u2019s successful at reining in the billions of dollars that drug companies spend on ads each year in the U.S.  It remains unclear what impact these government mea",
      "url": "https://finnhub.io/api/news?id=83781c4c6edbf9d5214a2a3bd1c314075e02f999ffa209003a3348c114a1f94d"
    },
    {
      "headline": "Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery",
      "source": "Yahoo",
      "datetime": 1757533269,
      "summary": "On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing ",
      "url": "https://finnhub.io/api/news?id=ee984ac60441273d969303c6092d69723f2f9335248ccf0a667b95d9ab7d41a7"
    },
    {
      "headline": "5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds",
      "source": "Yahoo",
      "datetime": 1757520480,
      "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.",
      "url": "https://finnhub.io/api/news?id=53beb53f11265427115a0250ab7c4556b4541be721f51f199478620ba03e385e"
    },
    {
      "headline": "J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum",
      "source": "Yahoo",
      "datetime": 1757520120,
      "summary": "J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.",
      "url": "https://finnhub.io/api/news?id=1c6b7357ed95e1f906ff01a9c73662da70f04a51d4529120bacc2c8e3e24db5a"
    },
    {
      "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach and SIFCO Industries",
      "source": "Yahoo",
      "datetime": 1757516700,
      "summary": "Zacks highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach, and SIFCO Industries in its latest research roundup, showcasing both blue-chip resilience and micro-cap growth stories.",
      "url": "https://finnhub.io/api/news?id=3ee50f1e7cd2cebf16a92d61ad92765b3ac75dc25928827bd59d1cbee83b739a"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "8-K",
      "date": "2025-09-09",
      "description": "jnj-20250908.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000190/jnj-20250908.htm"
    },
    {
      "form": "4",
      "date": "2025-09-05",
      "description": "xslF345X05/wk-form4_1757109644.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000186/xslF345X05/wk-form4_1757109644.xml"
    },
    {
      "form": "4",
      "date": "2025-09-03",
      "description": "xslF345X05/wk-form4_1756934034.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000184/xslF345X05/wk-form4_1756934034.xml"
    },
    {
      "form": "4",
      "date": "2025-08-25",
      "description": "xslF345X05/wk-form4_1756163533.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000182/xslF345X05/wk-form4_1756163533.xml"
    },
    {
      "form": "4",
      "date": "2025-08-18",
      "description": "xslF345X05/wk-form4_1755555550.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000180/xslF345X05/wk-form4_1755555550.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}